A S X : E X L | H A L F - Y E A R E N D E D 3 0 J U N E 2 0 2 6 US Divestment Completion & Business Update September 2026 Elixinol Wellness Limited ASX Code: EXL Building on a stabilised, higher-margin Australian nutrition and wellness platform Based on the Audited Interim financial statements for the half-year ended 30 June 2026 Important Notice & Disclaimer The following material is for general information purposes only and should not be relied on for the making of any investment decision. Any investment in Elixinol Wellness Limited ACN 621 479 794 (Elixinol Wellness) is subject to a number of investment risks including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Elixinol Wellness nor any other entity or person in or associated with the Elixinol Wellness group of companies guarantees any return (whether capital or income) or generally the performance of Elixinol Wellness or the price at which its securities may trade. In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Elixinol Wellness securities. This presentation is not exhaustive of all of the information a potential investor, or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act. This presentation does not take into account any specific objectives, financial situation or needs of investors. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk. This presentation may contain "forward-looking statements" which are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward-looking statements. Any forward-looking statements in this presentation should be considered “at-risk statements” - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward-looking statement. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof and Elixinol Wellness does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. In addition, the past performance of Elixinol Wellness cannot be assumed as indicative of the future performance. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined in this Presentation. Neither Elixinol Wellness nor any of its advisers, agents or employees make or give any express or implied representation, warranty or guarantee that the information contained in this presentation or otherwise supplied by or on behalf of Elixinol Wellness is complete or accurate or that it has been or will be audited or independently verified, or that reasonable care has been or will be taken in compiling, preparing or furnishing the relevant information. Elixinol does not take any responsibility for any inference, interpretation, opinion or conclusion that any person may draw or form from this presentation. To the maximum extent permitted at law, Elixinol Wellness and all of its representatives, directors, partners, employees or professional advisers exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), they do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this Presentation or any accompanying, previous or subsequent material or presentation. This Presentation is current as at 7 September 2026 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update 2 01 Transformational H1 FY26 Results Performance highlights and earnings drivers for the half 02 US Business Divestment Transaction rationale, terms and completion timeline 03 Stabilisation of the Capital Base Convertible note structure, proceeds and balance sheet impact Key Messages 04 Positioned for Growth Section two: the platform, market shift and innovation pipeline behind the next phase 3 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update H1 FY2026 RESULTS Materially improved half with increased margins and operational efficiency GROUP REVENUE (CONTINUING OPS) H1 FY25 $6.8m → $7.2m +5.8% GROSS MARGIN (CONTINUING OPS) H1 FY25 33.5% → 43.2% +9.8 pts ADJUSTED EBITDA LOSS H1 FY25 $(2.1)m → $(0.1)m +94% STATUTORY LOSS AFTER TAX H1 FY25 $(3.1)m → $(1.1)m +65.4% BASIC LOSS PER SHARE H1 FY25 (1.39)c → (0.26)c improved CASH AT PERIOD END H1 FY25 $1.1m → $1.0m -8% Gross margin and Adjusted EBITDA are calculated on a continuing-operations basis, consistent with Note 5 and the Directors' Report EBITDA reconciliation in the Audited Interim financial statements for the half-year ended 30 June 2026. 4 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update EARNINGS QUALITY Adjusted EBITDA improvement of +$2.0M on the prior half H1 FY26 $'000 H1 FY25 $'000 Loss after income tax (973) (2,941) Add back: Finance costs 223 279 Less: Interest income (4) (4) Add back: Depreciation & amortisation 374 511 EBITDA (380) (2,155) Add back: Impairment & write-off of assets 123 262 Add back/(deduct): Share-based payments 20 (101) Add back/(deduct): Non-operating transactions 103 (100) Adjusted EBITDA (134) (2,094) WHAT DROVE THE IMPROVEMENT • Gross profit increased $0.84 million to $3.11 million. • Gross margin expanded 9.8 percentage points through improved brand and product mix. • Core operating expenses reduced $1.08 million to $3.33 million. • The improvement was achieved without the $0.48 million insurance recovery received in H1 FY25. Source: Elixinol Wellness Interim Report, 30 June 2026 — Directors' Report EBITDA reconciliation. 5 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update A U S T R A L I A S E G M E N T P E R F O R M A N C E Australian brands drive revenue growth of +5.8% Key Brands ($'000) H1 FY25 H1 FY26 Change Hemp Foods Australia 2,516 2,871 +14.1% The Healthy Chef 1,694 2,070 +22.2% Hemp Ingredients 1,139 1,326 +16.4% Australia total 6,795 7,186 +5.8% Australia is the primary continuing operating segment presented here. Brand splits are per management reporting; Americas (Elixinol LLC, held for sale) and Rest of World are excluded from this view. KEY BRAND HIGHLIGHTS (H1 FY26) Hemp Foods Australia: $2.87m, +$0.36m (+14.1%); gross margin to 48% The Healthy Chef: $2.07m, +$0.38m (+22.2%); e-commerce & Priceline-led Hemp Ingredients: $1.33m, +$0.19m (+16.4%); gross margin to 38% Source: Interim Report Note 4 (Operating segments) and Company brand reporting. Australian segment only; Brand $ figures unaudited management splits. 6 Key Australian brand revenue by half ($M) 2.5 1.7 1.1 2.9 2.1 1.3 Hemp Foods Australia The Healthy Chef Hemp Ingredients H1 FY26 H1 FY25 Growth was partly offset by a $0.5M decline from Mt Elephant’s retailer consolidation and discontinued duplicate hemp brands. Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update PORTFOLIO & CORPORATE ACTIONS Simplifying the portfolio, lowering costs 1 Non-core US business sale The Group to divest Elixinol LLC (US), held for sale / discontinued at 30 June 2026 ($181k assets, $354k liabilities). Discontinued loss narrowed to $98k (H1 FY25: $152k). Completion subject to definitive documentation and the satisfaction of customary conditions precedent. 2 Small Parcel Sale Facility completed Established 20 April 2026 for sub-marketable holdings; completed 18 June 2026 — 7,387 shareholders, 18.8m shares sold at $0.006. 3 Operating platform streamlined Operating expenses reduced by $1.1M, or 25%, to $3.3M, reflecting lower employee, marketing, distribution and administration costs. 4 Funding flexibility added Subsequent to period end, the Group's Convertible Note offer approved at the AGM has closed, with subscriptions totalling $1,055,000 received. 7 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update BALANCE SHEET Balance sheet held broadly steady through the reshaping Group ($'000) 30 Jun 2026 31 Dec 2025 Movement Cash and cash equivalents 996 1,405 (409) Total current assets 5,425 5,700 (275) Total non-current assets 9,745 10,264 (519) Total assets 15,170 15,964 (794) Total current liabilities 6,972 6,642 330 Total non-current liabilities 1,834 1,870 (36) Total liabilities 8,806 8,512 294 Net assets / Total equity 6,364 7,452 (1,088) NET TANGIBLE ASSETS / SHARE* (0.54)c vs (1.12)c at 30 Jun 2025 NET ASSETS $6.4m vs $7.5m at 31 Dec 2025 SHARES ON ISSUE 414.0m unchanged in H1 FY26 *Net tangible assets per Appendix 4D compares 30 Jun 2026 to the prior corresponding half (30 Jun 2025), not 31 Dec 2025. Source: Interim Report — Consolidated Statement of Financial Position, Note 3 (NTA), Note 2 (Going concern). 8 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update CASH FLOW Underlying Operating1 cash flow turned positive CLOSING CASH (STATEMENT OF CASH FLOWS) $1.0m H1 FY25: $1.1m RECEIPTS FROM CUSTOMERS $7.42m H1 FY25: $7.95m UNDERLYING Q2 OPERATING CASH FLOW +$0.05m 3rd consecutive positive quarter Source: Interim Report — Consolidated Statement of Cash Flows; Q2 FY26 Appendix 4C (28 July 2026). 1. Underlying operating cash excludes financing costs, payments for income taxes and other items (timing adjustments and nonrecurring items). 9 -1.15 -0.03 1.44 0.07 0.01 0.31 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 Underlying Operating Investing Financing +1.22 H1 FY26 H1 FY25 Net cash flow by activity ($M) Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update US Divestment: Sharpening Our Australian Focus Sharper strategic focus Resources and management attention concentrated on our Australian health and wellness brands, where the strongest profitable growth opportunities sit. Lower regulatory risk Removes uncertainty tied to the evolving US regulatory framework for hemp-derived products, which were not material to earnings or net assets. The natural owner Ananda Health brings vertically integrated US manufacturing, market infrastructure and sector experience to support the brand's next phase. Transaction snapshot Headline consideration of A$465,000 — A$250,000 on completion plus deferred, contingent and earn-out payments. Completion occurred on 4th of September 2026. EXL retains the Elixinol brand outside the US. 10 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update Convertible Note: A Stronger Capital Base A$1.06m Offer attracted 1,055,800 notes at A$1.00 face value 12% p.a. Fixed coupon, payable annually 31 Dec 2027 Maturity date, converting to EXL ordinary shares 26 Aug 2026 Notes issued and funds received Why it matters Approved by shareholders at the AGM on 27 May 2026, the raise strengthens working capital to support growth across our Australian health and wellness brands. Notes convert to ordinary shares only on holder notice or at maturity, so dilution is deferred, and proceeds from the US divestment further support the capital base. 11 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update S E C T I O N T W O • F U T U R E A N D G R O W T H Reset to Growth The platform, the market and the pipeline behind the next phase Phase 01 Reset FY25 – H1 FY26 Costs rebased, portfolio simplified, US exposure exited and the capital base stabilised. Phase 02 Proof H2 FY26 Priceline rollout, Mt Elephant in grocery and hemp supplying two major retailers. Phase 03 Growth FY27 and beyond Functional nutrition and peptide innovation, B2B and private label, plus selective acquisitions. 12 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update A Wellness Platform: Four Brands, Each With a Clear Purpose The Healthy Chef Women's strength, vitality and healthy ageing Premium ecommerce and pharmacy Mt Elephant Better-for-you indulgence and family wellness National grocery expansion Hemp Foods Australia Plant-based nutrition and ingredient credibility Australia's largest hemp foods business B2B Ingredients Nature-led innovation, private label and B2B growth Contracted supply into two major grocers One platform Four brands share sourcing, manufacturing, quality systems and distribution across grocery, pharmacy, health food, ecommerce and B2B — so each new product and channel win compounds across the Group. 13 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update Australia's Largest Hemp Foods Company A vertically integrated platform connecting contracted supply, Australian processing and established retail relationships. 2 major grocery retailers supplied under contracted arrangements 2027 existing supply contracts extend to this date 4 processing streams: dehulling, seeds and oil, protein, private label Why it matters Contracted supply → Australian processing → Branded + private label → Retail + B2B channels Scale and reliable supply create a defensible base for branded products, private label and B2B ingredient growth. 14 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update The Healthy Chef Is Emerging as a Core Growth Engine A$2.07m H1 FY26 revenue +22.2% growth vs H1 FY25 29% of Australian segment revenue +A$0.38m revenue added year on year Premium ecommerce base Direct customer relationships and repeat purchase Pharmacy scale Priceline rollout across ~410 stores Functional innovation New formats in protein, metabolism and healthy ageing 15 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update Priceline Puts The Healthy Chef in Front of a National Audience ~410 Priceline Pharmacy stores in the Stage 1 rollout Pharmacy distribution gives The Healthy Chef mass physical visibility alongside its premium ecommerce base — reaching new customers where health advice is already sought. Stage 1 rollout underway, with broader pharmacy awareness activity to follow. 01 Discovery — pharmacy visibility at national scale 02 Trial — accessible entry formats and price points 03 Repeat — retail plus ecommerce subscription 16 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update The Wellness Market Is Shifting Toward Healthy Ageing US$6.8tn global wellness economy in 2024 US$9.8tn projected size by 2029 Up to 60% of consumers rank healthy ageing a top or very important priority Where EXL plays The opportunity sits where everyday nutrition meets strength, metabolism, sleep and long-term health — precisely the space our brands and pipeline are built for. Sources: Global Wellness Institute, 2025 Global Wellness Economy Monitor (Nov 2025); McKinsey & Company, Future of Wellness. 17 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update The Portfolio Already Has a Credible Entry Point 01 Protein waters Lighter, convenient protein for everyday use On shelf now 02 Metabolic burn Everyday metabolic support On shelf now 03 Nutritional peptides Sleep, muscle and expanded weight management Pipeline From now to next Existing products already establish demand and consumer permission in protein and metabolic support. The pipeline extends that permission into adjacent, higher-value needs — sleep, muscle maintenance and weight management — using the same brands, channels and manufacturing base. 18 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update Growth Comes From Four Practical Engines 01 Product innovation Build around protein, healthy ageing, convenience and better-for-you indulgence. 02 Channel expansion Scale through ecommerce, grocery, pharmacy, health food and B2B. 03 Operating discipline Protect margin, share capability across brands and allocate capital carefully. 04 Selective acquisition Add aligned brands or capabilities that strengthen the platform. Each engine is already in motion — the roadmap is about sequencing, not starting from scratch. 19 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update The Next 6–12 Months Offer Multiple Proof Points Retail Priceline rollout and broader pharmacy awareness Grocery Mt Elephant national expansion and new formats Innovation Functional nutrition and nutritional peptide pipeline Portfolio Continued mix improvement and B2B opportunities Capital Convertible note in place and disciplined assessment of aligned acquisitions 20 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update Re-Rating Upside as Growth Is Priced In EXL's current valuation provides a low starting point as the Group moves from reset to growth. A$3.5m market capitalisation A$0.008 per share on 438.2m shares, at 04 September 2026 A$14.4m L12M revenue A$5.9m L12M gross profit 0.24× market cap / revenue Pathway to recognition The disconnect is the opportunity: operating performance has changed, but that shift is not yet reflected in the share price. Consistent growth, sustained margins and continued cash discipline can progressively reshape how the market values EXL. L12M refers to the last 12 months ending 31 July 2026, excluding the US business. 21 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update E L I X I N O L W E L L N E S S | A S X : E X L A stronger foundation. A clearer position. A growing pipeline. We are building a scalable wellness platform in categories supported by long-term consumer demand. LIVE WELL LIVE STRONG AGE BETTER investorhub.elixinolwellness.com Elixinol Wellness Limited For further information: Natalie Butler, CEO & Executive Director natalie.butler@elixinolwellness.com ASX code: EXL | www.elixinolwellness.com https://investorhub.elixinolwellness.com/link/ej6Zxe This presentation has been prepared from the Audited Interim financial statements for the half-year ended 30 June 2026 (Directors' report dated 31 August 2026). 23 Elixinol Wellness Limited | ASX: EXL | US Divestment Completion & Business Update